Other studies have shown that tumor microenvironment can secrete inhibitory factor TGF-β1 to prevent effective anti-tumor immune response and blocking TGF-β signaling has emerged as a potential therapeutic approach for tumor treatment [28, 29]. The gene discussed is TGFB1; the disease is neoplasm.